Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein

Abstract Aims With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells. Main methods Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells. Key findings We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the world's population. Furthermore, we predicted CD4+ T-cell epitopes and B-cell epitopes. Significance Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes.

[1]  Yuan Wei,et al.  A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 , 2020, The New England journal of medicine.

[2]  Morten Nielsen,et al.  Improved method for predicting linear B-cell epitopes , 2006, Immunome research.

[3]  A. K,et al.  Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study , 2020, Journal of biomolecular structure & dynamics.

[4]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[5]  A. Alam,et al.  From ZikV genome to vaccine: in silico approach for the epitope‐based peptide vaccine against Zika virus envelope glycoprotein , 2016, Immunology.

[6]  M. L. Serrano,et al.  Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis , 2020, EXCLI journal.

[7]  Young-Jun Park,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[9]  Chonggang Xu,et al.  High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[10]  Chloe H. Lee,et al.  In silico identification of vaccine targets for 2019-nCoV , 2020, F1000Research.

[11]  Shibo Jiang,et al.  Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells , 2009, Biochemical and Biophysical Research Communications.

[12]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[13]  John Sidney,et al.  Predicting population coverage of T-cell epitope-based diagnostics and vaccines , 2006, BMC Bioinformatics.

[14]  E. Emini,et al.  Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide , 1985, Journal of virology.

[15]  Mei U Wong,et al.  COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning , 2020, bioRxiv.

[16]  Robert Adamu Shey,et al.  In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases , 2019, Scientific Reports.

[17]  E. Holmes,et al.  Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China , 2020, bioRxiv.

[18]  G. Gao,et al.  Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2 , 2020, Cell.

[19]  S. Sinha,et al.  An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets , 2020, Journal of biomolecular structure & dynamics.

[20]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[21]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[22]  A. Rodríguez-Morales,et al.  A vaccine is not too far for COVID-19. , 2020, Journal of infection in developing countries.

[23]  P. Y. Chou,et al.  Empirical predictions of protein conformation. , 1978, Annual review of biochemistry.

[24]  Magdalini Moutaftsi,et al.  A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.

[25]  Steven G E Marsh,et al.  The IPD-IMGT/HLA Database - New developments in reporting HLA variation. , 2016, Human immunology.

[26]  Pierre Tufféry,et al.  PEP-FOLD: an online resource for de novo peptide structure prediction , 2009, Nucleic Acids Res..

[27]  C. Chakraborty,et al.  Development of epitope‐based peptide vaccine against novel coronavirus 2019 (SARS‐COV‐2): Immunoinformatics approach , 2020, Journal of medical virology.

[28]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[29]  Rodrigo Lopez,et al.  The EMBL-EBI bioinformatics web and programmatic tools framework , 2015, Nucleic Acids Res..

[30]  E E Hughes,et al.  Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model. , 1995, Vaccine.

[31]  Shibo Jiang,et al.  A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2013, PloS one.

[32]  S. Schultz-Cherry,et al.  Immunology of avian influenza virus: a review. , 2000, Developmental and comparative immunology.

[33]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[34]  U. Wahn,et al.  T-cell co-stimulatory molecules: their role in allergic immune reactions , 2007, European Respiratory Journal.

[35]  R. Jacobson,et al.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. , 2011, Omics : a journal of integrative biology.

[36]  Syed Faraz Ahmed,et al.  Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies , 2020, Viruses.

[37]  Jiang Gu,et al.  Progress and Prospects on Vaccine Development against SARS-CoV-2 , 2020, Vaccines.

[38]  Epitope-Based Immunoinformatics Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-2 , 2020, Molecules.

[39]  Rino Rappuoli,et al.  Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery , 2019, Front. Immunol..

[40]  Deborah Fass,et al.  Core Structure of gp41 from the HIV Envelope Glycoprotein , 1997, Cell.

[41]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[42]  T. Emran,et al.  In vivo and in vitro pharmacological activities of Tacca integrifolia rhizome and investigation of possible lead compounds against breast cancer through in silico approaches , 2019, Clinical Phytoscience.

[43]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[44]  J. Leibowitz,et al.  The structure and functions of coronavirus genomic 3′ and 5′ ends , 2015, Virus Research.

[45]  P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .

[46]  J. Harty,et al.  CD8 T cell memory development: CD4 T cell help is appreciated , 2007, Immunologic research.

[47]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[48]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[50]  J. Kanne,et al.  Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist , 2020, Radiology.

[51]  Lu Lu,et al.  Receptor-binding domain as a target for developing SARS vaccines. , 2013, Journal of thoracic disease.

[52]  P. Karplus,et al.  Prediction of chain flexibility in proteins , 1985, Naturwissenschaften.

[53]  Michael J E Sternberg,et al.  The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.

[54]  David Nemazee,et al.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies , 2016, Cell.

[55]  P. Tongaonkar,et al.  A semi‐empirical method for prediction of antigenic determinants on protein antigens , 1990, FEBS letters.

[56]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[57]  H. Koohy,et al.  In silico identification of vaccine targets for 2019-nCoV. , 2020, F1000Research.

[58]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[59]  S. Chakraborty,et al.  In silico predicted mycobacterial epitope elicits in vitro T-cell responses. , 2014, Molecular immunology.

[60]  D. Eisenberg,et al.  VERIFY3D: assessment of protein models with three-dimensional profiles. , 1997, Methods in enzymology.

[61]  Mujahed I. Mustafa,et al.  Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach , 2020, BioMed research international.

[62]  Wei Li,et al.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines , 2007, BMC Bioinformatics.

[63]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[64]  Irini A. Doytchinova,et al.  AllerTOP - a server for in silico prediction of allergens , 2013, BMC Bioinformatics.

[65]  G. Chang,et al.  Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein. , 2012, The Journal of general virology.

[66]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[67]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[68]  Yue Chen,et al.  Evolution and variation of 2019-novel coronavirus , 2020, bioRxiv.

[69]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[70]  Irini A. Doytchinova,et al.  BMC Bioinformatics BioMed Central Methodology article VaxiJen: a server for prediction of protective antigens, tumour , 2007 .

[71]  Denis Hochstrasser,et al.  A Totally Synthetic Polyoxime Malaria Vaccine Containing Plasmodium falciparum B Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types1 , 2001, The Journal of Immunology.

[72]  G. Gao,et al.  Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development , 2011, Experimental biology and medicine.

[73]  Lisa E. Gralinski,et al.  Return of the Coronavirus: 2019-nCoV , 2020, Viruses.

[74]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[75]  Md. Anayet Hasan,et al.  A Computational Assay to Design an Epitope-Based Peptide Vaccine Against Saint Louis Encephalitis Virus , 2013, Bioinformatics and biology insights.

[76]  R. Chapman,et al.  Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus , 1999, Hepatology.

[77]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[78]  Shibo Jiang,et al.  Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine , 2004, Biochemical and Biophysical Research Communications.

[79]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[80]  Bjoern Peters,et al.  Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes , 2011, Immunogenetics.

[81]  S. Ribeiro,et al.  CD4+ T Cell Epitope Discovery and Rational Vaccine Design , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[82]  V. Arumugaswami,et al.  Insights into Cross-species Evolution of Novel Human Coronavirus SARS-CoV-2 and Defining Immune Determinants for Vaccine Development , 2020, bioRxiv.

[83]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[84]  R. Siezen,et al.  others , 1999, Microbial Biotechnology.

[85]  J. Corbeil,et al.  MHC-NP: predicting peptides naturally processed by the MHC. , 2013, Journal of immunological methods.

[86]  J. Hazes,et al.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. , 2000, Arthritis and rheumatism.

[87]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[88]  D. Veesler,et al.  Structural insights into coronavirus entry , 2019, Advances in Virus Research.

[89]  Mikael Bodén,et al.  PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity , 2013, BMC Bioinformatics.

[90]  D. Tyrrell,et al.  Cultivation of viruses from a high proportion of patients with colds. , 1966, Lancet.